Showing results (41-50 of 91) with videos related to
Sort By:
Pageof 10
Journal of Clinical Lipidology|December 10, 2013
Modest diet-induced weight loss reduces macrophage cholesterol efflux to plasma of patients with metabolic syndromeMadhuri Vasudevan, Urbain Tchoua, Baiba K Gillard, et al.The American Journal of Cardiology|February 2, 2008
Effects of maximal doses of atorvastatin versus rosuvastatin on small dense low-density lipoprotein cholesterol levelsMasumi Ai, Seiko Otokozawa, Bela F Asztalos, et al.Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|May 13, 2006
Effectiveness and tolerability of adding ezetimibe to niacin-based regimens for treatment of primary hyperlipidemiaNicole E Jelesoff, Christie M Ballantyne, Antonios M Xydakis, et al.The American Journal of Cardiology|October 13, 2016
Safety of Alirocumab (A PCSK9 Monoclonal Antibody) from 14 Randomized TrialsPeter H Jones, Harold E Bays, Umesh Chaudhari, et al.The American Journal of Cardiology|September 18, 2004
Effectiveness and tolerability of ezetimibe add-on therapy to a bile acid resin-based regimen for hypercholesterolemiaAntonios M Xydakis, John R Guyton, Philip Chiou, et al.The American Journal of Cardiology|January 27, 2005
Effects of rosuvastatin, atorvastatin, simvastatin, and pravastatin on atherogenic dyslipidemia in patients with characteristics of the metabolic syndromePrakash C Deedwania, Donald B Hunninghake, Harold E Bays, et al.Clinical Cardiology|October 2, 2014
Efficacy and safety of alirocumab as add-on therapy in high-cardiovascular-risk patients with hypercholesterolemia not adequately controlled with atorvastatin (20 or 40 mg) or rosuvastatin (10 or 20 mg): design and rationale of the ODYSSEY OPTIONS StudiesJennifer G Robinson, Helen M Colhoun, Harold E Bays, et al.Current Medical Research and Opinion|December 23, 2003
Comparison of the efficacy of rosuvastatin versus atorvastatin, simvastatin, and pravastatin in achieving lipid goals: results from the STELLAR trialJames M McKenney, Peter H Jones, M Angeli Adamczyk, et al.Journal of Clinical Lipidology|February 5, 2011
Efficacy and tolerability of multidrug therapy for hypertriglyceridemiaVenkateshwar R Polsani, Vijay Nambi, Salim S Virani, et al.Cardiovascular Drugs and Therapy|March 19, 2011
Long-term efficacy of adding fenofibric acid to moderate-dose statin therapy in patients with persistent elevated triglyceridesChristie M Ballantyne, Peter H Jones, Maureen T Kelly, et al.Pageof 10